Oncolytics Biotech (ONCY) Tax Provisions (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Tax Provisions of $183112.0 for Q3 2025, up 2181.61% year-over-year from $8025.6 in Q3 2024, and up 398.49% quarter-over-quarter from -$61345.6 in Q2 2025.
Oncolytics Biotech (ONCY) Tax Provisions (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Tax Provisions for 15 consecutive years, with $183112.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Tax Provisions rose 2181.61% year-over-year to $183112.0; the TTM figure through Sep 2025 stood at $96505.3 (up 183.87% YoY), while the FY2025 annual figure was $79000.0, down 16.84% from the prior year.
- Tax Provisions improved to $183112.0 in Q3 2025 per ONCY's latest filing, from -$61345.6 in the prior quarter.
- Across five years, Tax Provisions topped out at $183112.0 in Q3 2025 and bottomed at -$69458.4 in Q2 2024.
- Historically, Tax Provisions has averaged -$5309.0 across 5 years, with a median of -$16464.5 in 2024.
- Annual changes were most pronounced in 2023 — Tax Provisions sank 240.5% — and 2025, when it jumped 2181.61%.
- Oncolytics Biotech's Tax Provisions stood at $44546.6 in 2021, then plunged by 194.27% to -$41992.1 in 2022, then increased by 24.78% to -$31585.0 in 2023, then soared by 47.87% to -$16464.5 in 2024, then soared by 1212.16% to $183112.0 in 2025.
- Business Quant data shows ONCY's Tax Provisions at $183112.0 in Q3 2025, -$61345.6 in Q2 2025, and -$16464.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | 101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 101,000.00 |
| Sep 30, 2025 | 183,112.02 |
| Jun 30, 2025 | -61,345.56 |
| Dec 31, 2024 | -16,464.53 |
| Sep 30, 2024 | -8,796.64 |
| Jun 30, 2024 | -69,458.35 |
| Dec 31, 2023 | -31,585.03 |
| Sep 30, 2023 | -5,221.51 |
| Jun 30, 2023 | -34,989.27 |
| Dec 31, 2022 | -41,992.07 |
| Sep 30, 2022 | -1,533.49 |
| Jun 30, 2022 | -19,608.52 |
| Dec 31, 2021 | 44,546.61 |
| Sep 30, 2021 | -5,680.82 |
| Sep 30, 2018 | -79.00 |
| Jun 30, 2018 | -547,758.00 |
| Mar 31, 2018 | -120.00 |
| Sep 30, 2017 | 168.00 |
| Jun 30, 2017 | 89.00 |
| Mar 31, 2017 | 63.00 |